Will biotech investors cheer the impending round of IPOs?

A half-dozen biotech IPOs will roll out over the next 8 days, on top of 22 first-time public offerings in the industry so far this year. This batch has a combined money-raising goal of $350 million. Will investors cooperate with those hopes? Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…